Tesa-morelin vs NAD+

Tesamorelin and NAD+ are unrelated in mechanism and are marketed on an identical argument. Something measurable declines with age; restoring it should restore what was lost. Examining that argument is more useful than comparing the compounds.

Proxiva Compliance DeskResearch-use standards and labelling

What do these two actually have in common?

Almost nothing mechanistically, which makes the frequency of the pairing worth explaining.

Every row differs. What they share is not in the table: both are discussed within a narrative in which something falls with age and restoring it is proposed to undo the consequences of the fall.

That shared structure, rather than any shared biology, is what puts them in the same searches — and the structure itself deserves more scrutiny than either compound usually receives.

What is the decline argument, exactly?

Stated plainly it has three steps. A quantity is measured across ages and found to fall. The fall is associated with consequences considered undesirable. Restoring the quantity is therefore proposed to reverse those consequences.

The first two steps are frequently well supported. Both growth hormone axis output and NAD+ availability do decline measurably with age, and both declines are associated with a range of changes. Those are empirical observations and disputing them is not the point.

The third step is an inference, and it is where the argument becomes contestable. It requires that the decline causes the consequences. But a measured quantity falling alongside other changes is consistent with at least three different relationships, and only one supports the conclusion.

The decline may cause the consequences, in which case restoration should help. It may result from them — the body reducing something it no longer needs at the same rate, in which case restoration addresses a symptom. Or both may follow from a shared upstream cause, in which case restoration addresses neither.

Distinguishing these requires evidence that the declining measure is upstream of the consequences, and that evidence is a different and much harder thing to obtain than a correlation with age.

Does either compound clear that bar?

Neither fully, and they fall short in different places, which is the useful part.

For the growth hormone axis, an additional complication sits on top of the general problem. The axis does not merely produce less with age; its pattern of release changes. Endocrine axes signal partly through the shape of release over time rather than through amount alone, so restoring quantity without restoring pattern may not reproduce the earlier signal. Whether stimulating the axis achieves that is a real and open question, and it is separate from whether output can be raised at all.

For NAD+ the gap is one of distribution. That it is essential is settled and undisputed. Whether administering it raises the pool inside cells, where it would need to be raised to matter, is genuinely unresolved — cells maintain internal concentrations through dedicated machinery, and material in circulation is not automatically material inside a cell.

So one has an open question about whether stimulation reproduces the original signal, and the other has an open question about whether administered material arrives. Both are real gaps and neither is usually stated when the compounds are discussed.

Glutathione faces a close analogue of the second problem, for the same structural reasons, and is marketed within the same narrative.

Why does this matter more than the comparison?

Because it changes what evidence to look for, which a ranking would not.

Once the decline argument is visible as an argument rather than a background assumption, the useful questions become specific. Is there evidence that the declining measure is upstream of the consequences, rather than merely coincident with them? Has restoration been attempted and measured against an outcome, rather than against the measure itself? Does the intervention restore the pattern of the original signal or only its magnitude?

Those questions apply to both compounds and to a great deal else marketed in this category. They are more productive than asking which of two unrelated compounds is better, because they can actually be answered by reading, whereas the comparison cannot be answered at all.

They also identify a common failure in sources. Demonstrating that a measure was restored is easier than demonstrating that restoring it helped, and a great deal of writing presents the first as though it were the second. Noticing the substitution is most of the work.

What should be checked on arrival?

Both require a certificate matched to the batch in hand rather than a document representing a product line, with identity established before purity.

The two are chemically unalike and should not be characterised the same way. Tesamorelin is a synthesised peptide: read identity by mass spectrometry, then chromatographic purity as a trace rather than a headline figure, with peaks adjacent to the main peak treated as the finding of interest. It is a long enough synthesis for deletion sequences to be a genuine concern.

NAD+ is not a peptide. It is a nucleotide-derived coenzyme, and the appropriate analysis is that of a small molecule rather than a synthesised chain. A certificate presenting it in peptide terms indicates a supplier working from a template rather than commissioning analysis, and that observation generalises usefully beyond this compound.

Confirm quantity separately in both cases. Identity establishes what is present and purity establishes what else is; neither establishes how much.

How should each be handled?

Both arrive lyophilised, both are stable in that state under refrigeration, and both shorten considerably once reconstituted with bacteriostatic water where a vial will be entered more than once.

Direct diluent against the vial wall rather than onto the powder and allow dissolution rather than forcing it. Avoid repeated temperature cycling, which degrades material more reliably than any single handling error and is the least likely to be noticed at the time.

The quantities differ by roughly two orders of magnitude, which makes the reconstitution volumes and practical handling quite different in feel even though the principles are identical. Choose volume for the resolution of the measurement rather than for convenience; a solution too concentrated to measure accurately costs more in error than the additional diluent would have cost.

What has not been established?

No study has compared these two, and none would be expected to. An endocrine axis stimulant and a cellular coenzyme do not compete for any application, and there is no endpoint on which both have been measured.

Nor has any combination been examined. Nothing published addresses the pair, and any source discussing them together is working from the shared narrative rather than from evidence.

The most defensible summary is that both compounds have real biology behind them, both are attached to an argument whose weakest step is rarely examined, and the argument is more worth understanding than either compound is worth comparing. Recognising the structure once makes a large amount of writing in this category easier to assess.

Frequently asked questions

Research use only. All products referenced on this page are sold strictly for laboratory and research purposes. They are not drugs, foods, cosmetics, or medical devices, and they are not intended to diagnose, treat, cure, or prevent any disease. They are not for human or veterinary consumption. Handling should be performed only by qualified individuals in an appropriate laboratory setting.